research Good efficacy achieved by telitacicept in treatment of systemic lupus erythematosus with alopecia areata
Telitacicept effectively improved hair regrowth in a woman with lupus and alopecia.
Search
for
Sort by
Research
90-120 / 1000+ results 
research USE OF RITLECITINIB FOR THE TREATMENT OF ALOPECIA AREATA
Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.
research 067 BELCOMID: BELgian Cohort study of COVID-19 in Immune Mediated Inflammatory Diseases
COVID-19 infection rates were low in patients with immune diseases, regardless of their treatment type.
research PO:17:252 | The choice between belimumab and anifrolumab: analysis of a monocentric cohort
The choice between belimumab and anifrolumab depends on the specific symptoms of the patient's lupus.
research Selective complete Clq deficiency associated with systemic lupus erythematosus.
Clq deficiency is linked to systemic lupus erythematosus symptoms.
research Liarozole—a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate
Liarozole may be more effective than cyproterone acetate for treating advanced prostate cancer, with better PSA response and survival rates, while maintaining quality of life.
research 28665 Cutaneous T-cell lymphoma (CTCL) outcomes during COVID-19
CTCL patients can safely continue treatment during COVID-19 with proper safety measures.
research Cedrol mitigates hepatic lipid accumulation and adipocyte hypertrophy induced by corticosteroids through the inhibition of glucocorticoid receptor activity
Cedrol may help reduce liver fat and fat cell growth caused by corticosteroids.
research Baricitinib (Olumiant)
Baricitinib is effective and cost-efficient for treating severe alopecia areata in adults.
research Teriflunomide: a novel oral treatment for relapsing multiple sclerosis
Teriflunomide is an effective and safe first-line oral treatment for relapsing multiple sclerosis.
research Baricitinib: From Rheumatoid Arthritis to COVID‐19
Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.
research Drug Information Analysis Service
Cromolyn sodium's effectiveness for treating asthma in children under 2 is unclear, possibly more beneficial for older children, and further research is needed.
research A patient with Cronkhite-Canada syndrome whose entire digestive tracts was examined endoscopically
Prednisolone improved symptoms in a woman with Cronkhite-Canada syndrome, but regular screenings are needed due to cancer risk.
research Calcitriol ointment in the treatment of facial, hairline and retroauricular chronic plaque psoriasis
The ointment is a safe, effective, and well-tolerated treatment for certain types of psoriasis.
research Tofacitinib for the Treatment of Three Immune-mediated Conditions in One Patient: Ulcerative Colitis, Pyoderma Gangrenosum, and Alopecia Areata
Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.
research Drug pipeline 2Q22 — a downturn in approvals
Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.
research TNF-α Inhibitor-Induced Psoriasis and Psoriatic Alopecia in Adolescent with Ulcerative Colitis: Clinical Case
Ustekinumab effectively treated psoriasis and ulcerative colitis in a teen after infliximab caused complications.
research LB793 A phase 1, open-Label, single ascending dose study in healthy subjects of the safety, tolerability and pharmacokinetics of ASLAN004, a novel IgG anti-IL-13 receptor alpha 1 Inhibitor
ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.
research Exfoliative cutaneous lupus erythematosus in German shorthaired pointer dogs: disease development, progression and evaluation of three immunomodulatory drugs (ciclosporin, hydroxychloroquine, and adalimumab) in a controlled environment
Hydroxychloroquine showed some potential, but overall, the three drugs had limited success in treating lupus in dogs.
research An unusual case of ANCA positive disease
A 13-year-old girl with various symptoms was successfully treated with an antibiotic called co-trimoxazole.
research A Case Report of Cronkhite-Canada Syndrome Complicated by Membranous Nephropathy
Rituximab may be an effective treatment for Cronkhite-Canada syndrome with kidney disease.
research Lilly arthritis drug approved for alopecia
The drug Olumiant is now approved to treat severe hair loss from alopecia and can also be used for some hospitalized COVID-19 patients.
research Successful treatment of rare linear lichen planopilaris with Ixekizumab
Ixekizumab successfully treated a rare hair loss condition, leading to complete hair regrowth.
research Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
Ruxolitinib cream effectively targets and treats inflammatory skin diseases.
research 224 Humoral immune response to COVID-19 vaccination in psoriasis patients on biologic therapy is impaired compared to healthy controls
Psoriasis patients on biologic therapy have a weaker immune response to COVID-19 vaccination than healthy people.
research P718 Observational real-world evidence on the efficacy and safety of Janus Kinase inhibitors (JAKi) in the treatment of moderate to severe Active Ulcerative Colitis (UC)
Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.
research Comparative efficacy and safety of systemic steroids, oral JAK inhibitors and Contact Immunotherapy in the Treatment of severe alopecia areata: a systematic review and network meta-analysis
Oral ritlecitinib and baricitinib are promising treatments for severe alopecia areata due to their balance of effectiveness and safety.
research Biologics in the management of childhood atopic dermatitis
Biologics, especially Dupilumab, are effective and safe for treating severe childhood eczema.
research Calcipotriol/dithranol
research Recalcitrant lichen planopilaris and frontal fibrosing alopecia responding to tildrakizumab
Tildrakizumab significantly improved recalcitrant lichen planopilaris and frontal fibrosing alopecia.